MID
Desconocido
NanoCarb: Glyco Nanoparticles for Applications in Advance Nanomedicine
MIDATECH LTD
participó en un
H2020:
H2020-MSCA-ITN-2018
The advance of nanomedicine requires the development of novel materials with tailored properties, controlled circulation, optimal targeting...
2018-08-20 - 2023-03-31 | Financiado
2018-08-20 - 2023-03-31 | Financiado
NANOFACTURING: The Development of Medium and Large Scale Sustainable Manufacturing Process Platforms for Clinicall...
MIDATECH LTD
participó en un
H2020:
H2020-NMP-2014-2015
A number of nanomedicine formulations have enabled, or been shown to hold considerable potential for enabling more effective and less toxic...
2014-12-15 - 2019-01-31 | Financiado
2014-12-15 - 2019-01-31 | Financiado
EE-ASI: Beta cell preservation via antigen specific immunotherapy in Type 1 Diabetes Enhanced Epidermal Ant...
MIDATECH LTD
participó en un
FP7:
Current approaches to improving glycaemic control in type 1 diabetes are centered on increasingly complex insulin delivery systems. However...
Financiado
Financiado
* No se disponen de datos de la empresa actual.